Pathogenic in Medical Technology

Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens

... -- Since QR448(a) has been shown previously to be effective against pathogenic isolates of IBV and now against Arkansas vaccine virus, it is expected that it will also limit transmission of pathogenic IBV in broilers and thereby decrease the severity of the disease. ...

Teeth and Gums Also Benefit from the Healing Power of Aloe Vera

... (AGD) clinical, peer-reviewed journal. Aloe vera tooth gel is intended to perform the same function as toothpaste, which is to eliminate pathogenic oral microflora -- disease-causing bacteria -- in the mouth. The ability of aloe vera tooth gel to successfully perform that function has been a ...

Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures

... and Erlangen, Germany colleagues, have been utilizing complex information technology models to focus on genetic targets that quickly identify pathogenic bacteria. "The advantage of our RAPID2 system is that it provides an efficient framework for quickly identifying new biomarkers based on the genomic ...

Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease

... around this promising new therapeutic target. Ideal proposals will work to shed light on critical questions surrounding LRRK2, such as how LRRK2 pathogenic mutations directly lead to in vivo functional and pathological outcomes, and which cellular pathways LRRK2 normally and/or abnormally functions in. ...

Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories

... Thiboutot, M.D., a Phase III trial investigator, "Use of combination therapy is recommended at the initiation of acne therapy to inhibit multiple pathogenic factors. The new fixed combination, Acanya Gel, is an effective, safe, and well-tolerated topical product for treating patients with moderate to ...

Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder

... of all ages and backgrounds. More than 300,000 people in North America are estimated to have some form of dystonia. There is no cure. Since the pathogenic mechanisms of primary torsion dystonias are very poorly understood any new information about genetic causes of these diseases is desperately needed ...

Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials

... and colleagues is imaginative and original. If successful, this technology may provide an important new tool in the fight against MRSA and other pathogenic bacteria." Dr Fairhead also added that other SASP candidates in the Company's pipeline are being developed against C. difficile and E. ...

Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)

... Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr virus (EBV) and hepatitis C virus (HCV). Fred Volinsky, CEO 415 765 7193 ...

New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease

... may not be able to walk, talk, see or hear. "The demonstration by Dr. Chinnery and colleagues that at least one in 200 newborns harbor known pathogenic mitochondrial DNA mutations indicates that mitochondrial dysfunction is a major underlying risk factor for human disease," said Dr. Douglas C. ...

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial

... T regulatory cells. This unique mechanism of action has the potential to ameliorate autoimmune disease symptoms not only through its direct action on pathogenic CD4 T cells, but by impacting downstream effects of CD4 T cells such as B cell autoantibody production. About Tolerx In addition to the anti-CD4 ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

... of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of ...

Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU

... advantage of stimulating the vaccine protection directly at the site of virus entry. 2. Effective Immune Response Though the vaccine looks like a pathogenic influenza virus to the body, it does not cause disease. However, after intranasal application, the vaccine stimulates a strong immune response, which ...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

... pathophysiology of systemic sclerosis (SSc) and pivotal in the development of PAH in SSc, one of the leading causes of death in SSc. Endothelin, a pathogenic mediator, is implicated in the underlying vasculopathy in SSc. DUs can be a frequent, persistent and debilitating complication of SSc. They are ...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

... (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of ...

Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization

... studies conducted to date on QR448(a): -- The formulation was initially identified as QR441(a) and for its anti-viral activity against Highly pathogenic Avian Influenza H5N1. -- In-vitro anti-viral activity was shown against IBV at maximum effective non-toxic concentrations of QR448(a). -- In ...

Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model

... 1 diabetes pathogenesis, was also observed. "Inhibition of the Syk kinase has the potential to reduce both autoantibody production and disarm its pathogenic consequences," said Raphael Clynes M.D., Ph.D., assistant professor in Medicine and Microbiology at Columbia University's College of Physician's and ...

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, ...

BioCryst Updates Peramivir Clinical Development Plan

... of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, as of December 2007 at least 331 people have been infected with H5N1 avian influenza, of which at ...

Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, ...

Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies

... assay development, and sample characterization in order to expand the understanding of transmission of influenza viruses, including the highly pathogenic H5N1 avian influenza viral strain. "We are excited to be working with the Lovelace Respiratory Research Institute, a world leader in respiratory ...

Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors

... MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most ...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

... to recognize TCRs expressed by potentially pathogenic T cells. New data were also presented that showed ... of Foxp3+ Tregs against a broad population of pathogenic T cell families is also important as it provides ... Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides ...

NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus

... this rgH5N1 strain (Clade 1), confirming previous results. The Highly pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in ... each other, but closer to each other than to Clade 1 strains. "Highly pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus ...

Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference

... antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as "bird flu." Alferon-LDO is a ... Following exposure of the dosed and untreated test subjects to the highly pathogenic HPAI strain A/Vietnam/1194/04, throat and nasal swabs were taken, ...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis

... Vaccination For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in ...

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine

... Vical's lead Vaxfectin(TM)-formulated, DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly pathogenic strain of H5N1 influenza virus. Initial human testing of Vical's influenza DNA vaccine is expected to begin in the second half of 2007. Vical ...

New Report Illuminates Ampligen's Unique Mechanism of Action

... The findings further establish the remarkable specificity of Ampligen(R) in activating the critical first line of defense against various types of pathogenic elements. The findings are pertinent to many cutting edge therapeutic topics in biotechnology today, including the enhancement of vaccine efficacy ...

IR BioSciences Announces Promising Data from Study of Its Compound Homspera

... the current avian influenza endemic to Southeast Asia may mutate sufficiently to become more easily transmitted among humans, yet maintain its highly pathogenic nature. Such an event, centered on the virus currently exhibiting mortality in infected humans of approximately 50%, can trigger a rapid global ...

Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference

... a new scientific report on the activity of its experimental therapeutic Ampligen(R) in combination with approved anti-influenza agents against highly pathogenic avian influenza (HPAI), also known as bird flu. Tamiflu resistance by newly emerging strains of HPAI has been widely reported (New Engl. Journal ...

Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting

... Vaccination For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in ...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

... doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase ...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

... Vaccination For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in ...